Advances in Sickle Cell Disease Treatments

Area of Science:

• Hematology
• Genetics
• Pharmacology

Background:

• Sickle Cell Disease (SCD) is a severe inherited red blood cell disorder caused by a single gene mutation.
• Affecting millions globally, particularly in low-income regions, SCD leads to significant morbidity, mortality, and reduced life expectancy.
• Existing treatments have limited efficacy, highlighting the urgent need for novel therapeutic strategies.

Purpose of the Study:

• To review recent advancements in pharmacological and non-pharmacological treatments for Sickle Cell Disease.
• To focus on drug discovery strategies implemented over the last decade for SCD.
• To present emerging therapeutic alternatives and non-pharmacological approaches for managing SCD.

Main Methods:

• Review of recent scientific literature on Sickle Cell Disease treatments.
• Analysis of newly approved drugs and promising compounds for SCD symptom management.
• Discussion of non-pharmacological interventions such as gene therapy and stem cell transplantation.

Main Results:

• Few drug discoveries occurred between 1998 and the last three years.
• Voxelotor, crizanlizumab, and glutamine have been approved as new therapeutic alternatives.
• Promising new compounds and non-pharmacological strategies are emerging for SCD.

Conclusions:

• Recent years have seen significant progress in developing new treatments for Sickle Cell Disease.
• Approved drugs and ongoing research offer improved therapeutic options.
• Non-pharmacological approaches like gene therapy represent future directions for SCD management.